Page 52 - AN-3-1

Advanced Neurology Antibodies as neurodegenerative biomarkers

163. Burstein AH, Zhao Q, Ross J, et al. Safety and pharmacology RG7935, an Anti-α-Synuclein Monoclonal Antibody, in
of ponezumab (PF-04360365) after a single 10-minute Patients with Parkinson Disease: A Randomized Clinical
intravenous infusion in subjects with mild to moderate Trial. JAMA Neurol. 2018;75(10):1206-1214.
alzheimer disease. Clin Neuropharmacol. 2013;36(1):8-13.
doi: 10.1001/jamaneurol.2018.1487
doi: 10.1097/WNF.0b013e318279bcfa
168. Masliah E, Rockenstein E, Mante M, et al. Passive
164. Gustafsson G, Eriksson F, Möller C, et al. Cellular uptake of immunization reduces behavioral and neuropathological
α-Synuclein oligomer-selective antibodies is enhanced by deficits in an alpha-synuclein transgenic model of lewy
the extracellular presence of α-synuclein and mediated via body disease. PLoS One. 2011;6(4):e19338.
Fcγ receptors. Cell Mol Neurobiol. 2017;37(1):121-131.
doi: 10.1371/journal.pone.0019338
doi: 10.1007/S10571-016-0352-5
169. Schenk DB, Koller M, Ness DK, et al. First-in-human assessment
165. Lindström V, Fagerqvist T, Nordström E, et al. of PRX002, an anti-α-synuclein monoclonal antibody, in
Immunotherapy targeting α-synuclein protofibrils reduced healthy volunteers. Mov Disord. 2017;32(2):211-218.
pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol
Dis. 2014;69:13-143. doi: 10.1002/mds.26878
doi: 10.1016/J.NBD.2014.05.009 170. Weihofen A, Liu YT, Arndt JW, et al. Development of an
aggregate-selective, human-derived α-synuclein antibody
166. Shahaduzzaman M, Nash K, Hudson C, et al. Anti-human BIIB054 that ameliorates disease phenotypes in Parkinson’s
α-synuclein N-terminal peptide antibody protects against disease models. Neurobiol Dis. 2019;124:276-288.
dopaminergic cell death and ameliorates behavioral deficits
in an AAV-α-synuclein rat model of Parkinson’s disease. doi: 10.1016/j.nbd.2018.10.016
PLoS One. 2015;10(2):e0116841. 171. Brys M, Fanning L, Hung S, et al. Randomized phase I
doi: 10.1371/JOURNAL.PONE.0116841 clinical trial of anti-α-synuclein antibody BIIB054. Mov
Disord. 2019;34(8):1154-1163.
167. Jankovic J, Goodman I, Safirstein B, et al. Safety and
Tolerability of Multiple Ascending Doses of PRX002/ doi: 10.1002/mds.27738

Volume 3 Issue 1 (2024) 17 https://doi.org/10.36922/an.2058